DV
Dividend Vision

NVCR — NovoCure Limited

NovoCure Limited (NVCR)

Total return is -7.3% over the past 10.9 years, 382.4 points behind SPY at 375.1%. Its deepest 1-year drawdown was 32.5%.

NovoCure Limited is a single-stock equity holding focused on a medical device company specializing in tumor-treating field therapy for cancer treatment. The stock does not pay dividends or distributions, making it a non-yielding holding with no ongoing income component. This security appeals primarily to growth-oriented investors seeking exposure to innovative cancer treatment technology rather than income-focused investors.

NVCR key facts

Asset type
Stock
Asset class
Equity
Inception date
10/02/2015
Distribution frequency
None
Last close
$16.95
Market cap
$1,973,757,056
Average volume
681200.0
Beta
0.984
Payout ratio
0.0
Forward P/E
909.0909
EPS
$-1.30